MucAct

What is the clinical effectiveness and cost-effectiveness of nebulised saline in patients with chronic obstructive pulmonary disease? (MucAct COPD Trial)

We want to study whether breathing in salty water through a nebuliser can help patients with Chronic Obstructive Pulmonary Disease (COPD) cough up phlegm, make them feel better and cut down the number of chest infections. We also would like to know whether this is better than taking tablets (carbocisteine), also thought to help patients clear phlegm from the airways.

Chief Investigator: Professor Adam Hill 

Number and location of participating sites (by region/ country): 20 UK Sites

EudraCT number: 2020-001949-39

ISRCTN number:  TBC

Funder: National Institute for Health Research Health Technology Assessment Programme (NIHR HTA)

Start and End date

Of grant award: 01 June 2020

Of recruitment: October 2021

Current Status: Open to recruitment

Trial Website: No

Email: MucActCOPD@ed.ac.uk

UK GDPR Privacy Statement:

Sponsor: ACCORD (https://www.accord.ed.ac.uk/)

Chief Investigator:  Professor Adam Hill

Address: 102 West Port, Edinburgh, EH3 9DN

Email: adam.hill@nhs.scot

Trial Manager: Bea Selby  Email: MucActCOPD@ed.ac.uk

Research Nurse: Sam Donaldson Email: sam.donaldson1@nhs.net and Andrea Clarke Email: andrea.clarke8@nhs.net

ECTU involvement: Trial management / Statistics / Health Economics / Data base